161 results on '"Bernigaud, Charlotte"'
Search Results
2. New Treatment Solutions
3. Scabies-Associated Microbiota
4. Experimental Animal Models
5. Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors
6. Arthropods
7. 523 - Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD)
8. Lice, scabies, and myiasis
9. Activity of terpenes derived from essential oils against Sarcoptes scabiei eggs
10. The Challenge of Developing a Single-Dose Treatment for Scabies
11. Low Cross-Reactivity Between Cisplatin and Other Platinum Salts
12. Worldwide differences in clinical management practices of scabies: A survey using clinical vignettes.
13. Worldwide Differences in Clinical Management Practices of Scabies: a Survey Using Clinical Vignettes
14. Atypical bullous dermatosis: from suspected drug reaction to misdiagnosed occult epilepsy. Two challenging cases
15. Immunosuppressants as steroid-sparing agents for chronic DRESS: four cases
16. Les modèles animaux de la gale : quels sont-ils? Permettront-t-ils de découvrir de nouvelles stratégies thérapeutiques?
17. Essential oils as potential triggers for bullous pemphigoid? A report of two patients
18. Severe Scabies: A French Multi-centre Study Involving 95 Patients with Crusted and Profuse Disease and Review of the Literature
19. Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD).
20. 684 - Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY.
21. 661 - Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD).
22. Relapsing generalized bullous fixed drug eruption: A severe and avoidable cutaneous drug reaction. Three case reports
23. Zoonotic Episodes of Scabies: A Global Overview
24. High-dose ivermectin in malaria and other parasitic diseases: a new step in the development of a neglected drug
25. Anasarque chyleuse sur immuno-toxicité lymphatique du nivolumab chez une patiente avec mélanome métastatique
26. Granulomatose faciale 38 ans après des injections de produits de comblement : rôle précipitant de la COVID-19 et intérêt du méthotrexate
27. Subungual scraping for the diagnosis of common scabies: A prospective observational study
28. First evidence of the activity of an entomopathogenic fungus against the eggs of Sarcoptes scabiei
29. Syphilis has no age limit
30. Dermoscopy and confocal microscopy for in vivo detection and characterization of Dermanyssus gallinae mite
31. Ivermectin as a potential treatment for COVID-19?
32. First Description of the Composition and the Functional Capabilities of the Skin Microbial Community Accompanying Severe Scabies Infestation in Humans
33. Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract
34. Scabies-infested pregnant women: A critical therapeutic challenge
35. Non-Histaminergic Itch Mediators Elevated in the Skin of a Porcine Model of Scabies and of Human Scabies Patients
36. Missed Diagnosis of Epilepsy-Associated Scald Burns: Two Cases Initially Diagnosed as Bullous Dermatosis
37. How to eliminate scabies parasites from fomites: A high-throughput ex vivo experimental study
38. In Vitro Activity of Beauvericin against All Developmental Stages of Sarcoptes scabiei
39. Lemongrass (Cymbopogon citratus) oil: A promising miticidal and ovicidal agent against Sarcoptes scabiei
40. Missed Diagnosis of Epilepsy-Associated Scald Burns: Two Cases Initially Diagnosed as Bullous Dermatosis.
41. In vitro activity of beauvericin against all developmental stages of Sarcoptes scabiei
42. Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptes scabiei in the Porcine Scabies Model for Human Infestation
43. Health products e‐sale should be regulated: a case of necrotizing soft‐tissue infection of the abdomen linked to self‐injection of slimming products purchased on the internet.
44. The Management of Scabies in the 21st Century: Past, Advances and Potentials.
45. Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptesscabiei in the Porcine Scabies Model for Human Infestation
46. Scabies Itch
47. In vitro activity of ten essential oils against Sarcoptes scabiei
48. Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model
49. Are humans the initial source of canine mange?
50. Prospects for Moxidectin as a New Oral Treatment for Human Scabies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.